PRTO News and Press, Proteon Therapeutics Inc. From 08/07/19

Proteon Therapeutics (NASDAQ: PRTO ): Q2 GAAP EPS of -$0.27 misses by $0.14 . More news on: Proteon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its...

Proteon Therapeutics (NASDAQ: PRTO ): Q1 GAAP EPS of -$0.34  misses by $0.11 . More news on: Proteon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended ...

Aimed at boosting shareholder value, Proteon Therapeutics (NASDAQ: PRTO ) will explore strategic alternatives that could include an acquisition, merger or business combination. More news on: Proteon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its plans to explore a range of strategic ...

Proteon Therapeutics (NASDAQ: PRTO )  -83%  after vonapanitase flunks second late-stage study. More news on: Proteon Therapeutics, Inc., Reebonz Holding Limited, Castor Maritime Inc., Stocks on the move, Read more ...

A Phase 3 clinical trial, PATENCY-2 , evaluating Proteon Therapeutics' (NASDAQ: PRTO ) vonapanitase in chronic kidney disease (CKD) patients undergoing the creation of a radiocephalic fistula (vascular access in the wrist area) for hemodialysis failed to beat placebo . More news on: Prot...

WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced results from PATENCY-2, its Phase 3 clinical tria...

Proteon Therapeutics (NASDAQ: PRTO ): Q4 GAAP EPS of -$0.27. More news on: Proteon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...